Dr Nick Gonzalez MD: Enzyme Therapy of Cancer

Dr Nick Gonzalez MD

Dr Nick Gonzalez MD

Dr Gonzalez MD is internationally recognised as a leader in the enzymatic therapy of cancer. Dr Gonzalez graduated from Brown University, Phi Beta Kappa, magna cum laude with a degree in English Literature. He subsequently completed his premedical work as a postgraduate student at Columbia University, and received his medical degree from Cornell University Medical College in 1983. After his internship, he completed fellowship training in immunology under Robert A. Good, Ph.D., M.D., considered to be the father of modern clinical immunology. Dr. Gonzalez began researching nutritional approaches to cancer while a medical student, and completed an investigation of the enzyme therapy of cancer while an immunology fellow.

Dr Nick Gonzalez presented a fascinating, informed and clinically relevant day of lectures at the Royal Society of Medicine on 18th April 2009. This presentation was recorded.

Access seminar resources Missed a seminar? Read about our purchase option

You can now buy the seminar for only £12 and listen to the presentation, at your own leisure, providing 5.5/6 CPD credits and the opportunity to hear a world leader in the treatment of people diagnosed with cancer using nutritional medicine.

Just call +44(0)8450 760 402 to order and a link will be sent to you for the following:

Dr. Gonzalez has appeared several times on the popular Fox network national television show, to discuss his treatment and issues related to alternative medicine in general. During a visit on March 11, 2008, Dr. Gonzalez appeared in two segments, first with two of his patients, both seven year survivors of pancreatic adenocarcinoma. His patients, who beat the worst of odds, were the stars of the show. In a second segment, Dr. Gonzalez discussed his treatment with a pancreatic surgeon from Mt. Sinai Medical School.

Continuing Professional Development

CPD Approval Credits/hours
British Association for Applied Nutrition and Nutritional Therapy
British Association for Applied Nutrition and Nutritional Therapy
5.5
The Royal College of Physicians has awarded CPD credits for the seminar:Royal College of Physicans (RCP) 6

Photos from the Seminar

Click on a photo to enlarge.

For More Information About Dr. Gonzalez:

visit www.dr-gonzalez.com or use the links below to access specific informaiton.

Other areas that might interest you are:

New Publications 2009

In 2008 the 150th anniversary of the birth of Dr. Beard was celebrated. To commemorate this event Dr. Gonzalez has been comissioned to write a series of books celebrating and expanding on Dr. Beard’s innovative research.

The books will discuss in detail the history, theory and application of Dr. Beard and Dr. Gonzalez’s work.  The first available will be “Dr. Beard, the Trophoblast and the Origins of Cancer,” in which Dr. Gonzalez uses contemporary molecular biology to confirm what Beard said 100 years ago. One of the first four books will be a facsimile reproduction of Beard’s 1911 book, “The Enzyme Treatment of Cancer,” with a lengthy introduction by Dr. Gonzalez.

Nutr Cancer. 1999;33(2):117-24.

Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support.

Gonzalez NJ, Isaacs LL.

Historically, large doses of proteolytic enzymes, along with diet, nutritional supplements, and “detoxification” procedures, have been used in alternative therapies to treat all forms of cancer, without formal clinical studies to support their use. A 2-year, unblinded, 1-treatment arm, 10-patient, pilot prospective case study was used to assess survival in patients suffering inoperable stage II-IV pancreatic adenocarcinoma treated with large doses of orally ingested pancreatic enzymes, nutritional supplements, “detoxification” procedures, and an organic diet. From January 1993 to April 1996 in the authors’ private practice, 10 patients with inoperable, biopsy-proven pancreatic adenocarcinoma were entered into the trial. After one patient dropped out, an 11th patient was added to the study (however, all 11 are considered in the data tabulation). Patients followed the treatment at home, under the supervision of the authors. As of 12 January 1999, of 11 patients entered into the study, 9 (81%) survived one year, 5 (45%) survived two years, and at this time, 4 have survived three years. Two patients are alive and doing well: one at three years and the other at four years. These results are far above the 25% survival at one year and 10% survival at two years for all stages of pancreatic adenocarcinoma reported in the National Cancer Data Base from 1995. This pilot study suggests that an aggressive nutritional therapy with large doses of pancreatic enzymes led to significantly increased survival over what would normally be expected for patients with inoperable pancreatic adenocarcinoma.

View article at the NCBI website.

Integrative Cancer Therapies, Vol. 7, No. 4, 295-310 (2008)

DOI: 10.1177/1534735408327036

Exogenous Proteases Confer a Significant Chemopreventive Effect in Experimental Tumor Models

Martin Wald, MD

Department of Surgery, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic,

In this monograph, the chemopreventive effects of enterally administered proteases (trypsin, chymotrypsin, and papain) have been documented in a series of animal experimental tumor models. The experimental evidence demonstrates a significant inhibition of growth of both the primary tumor and the metastatic disseminations. Survival in animals treated with proteases is significantly longer than in untreated animals. The results confirm the fundamental correlation between early initiation of therapy and consequent growth of the tumorous disease. Comparable results have been shown in solid tumors in animal models (melanoma and Lewis lung carcinoma) and in human tumors (pancreatic and breast cancers). In this article, details of the known mechanisms of systemic actions of enterally administered proteases are documented and their relationship with cancerogenesis is discussed.

We use cookies and similar tools across our websites to improve their performance and enhance your user experience. Learn more about our Cookies Policy and click I understand, to hide this message.